Oral GLP-1 medication, brought to you on day one in partnership with Novo
The Bottom Line on GLP-1 Safety Research consistently shows that GLP-1 medications are safe for most people when used appropriately under medical supervision
Research suggests Pinealon has a low risk of dependency
If a bulk substance is not eligible under Section 503A, compounding pharmacies face enforcement risk for preparing it
In a randomized, double-blind, placebo-controlled trial, once-weekly exenatide (2 mg) administered for 48 weeks significantly improved motor scores in patients with PD, with benefits sustained even after treatment discontinuation ( Collectively, these findings indicate that incretin mimetics provide neuroprotection extending beyond metabolic regulation by targeting multiple pathogenic processes in PD, including mitochondrial dysfunction, neuroinflammation from oxidative stress, sirtuin dysregulation, insulin resistance, and S toxicity (Figure 2)